Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
632 Clinical update from a phase 1, first-in-human, open-label single agent study of SUPLEXA therapeutic cells in patients with metastatic solid tumours and haematologic malignancies
Compose a Response to This Article
Other responses
No responses have been published for this article.